BACKGROUND Rosiglitazone and pioglitazone are high-affinity peroxisome proliferator-activated receptor (PPAR)-gamma agonists with potent anti-diabetic properties and potential anti-inflammatory effects. We compared the ability of a range of oral doses of these thiazolidinediones, including those sufficient to restore insulin sensitization, to inhibit the pathogenesis of adjuvant-induced arthrit...

A linear quantitative structure-activity relationship (QSAR) model is presented for modeling and predicting the αglucosidase inhibitory activity. The model was produced by using the multiple linear regression (MLR) technique on a twenty one compound database that consists of newly discovered 2,4-thiazolidinediones. The major conclusion of this study is that molecular weight, wiener index, andre...

The peroxisome proliferator-activated receptor superfamily (PPARs) comprises a class of nuclear receptors with significant effects in regulating multiple cellular pathways. Much research and clinical interest has surrounded the PPAR-gamma isoform because of its key role in the transcriptional regulation of metabolic pathways and the efficacy of thiazolidinediones, the most clinically used PPAR-...

The prevalence of metabolic syndrome, obesity and insulin resistance has become an epidemic in the world. A strong association exists between metabolic syndrome and non-alcoholic fatty liver disease (NAFLD), though the etiology of NAFLD is still unclear. This close association leads to numerous clinical studies to investigate the effects of insulin sensitizers, thiazolidinediones (TZDs), on hep...

The invention of thiazolidinediones, also referred to as glitazones, has been one of the greatest developments in the treatment of Type II diabetes over the last two decades. Although the efficacy of the glitazones is substantial, their use has been limited by adverse effects including edema, weight gain and cardiac issues. While still being used for a specific subset of diabetic patients, much...